ANI Pharmaceuticals Company Profile (NASDAQ:ANIP)

About ANI Pharmaceuticals

ANI Pharmaceuticals logoANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company's focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ANIP
  • CUSIP:
Key Metrics:
  • Previous Close: $63.05
  • 50 Day Moving Average: $60.75
  • 200 Day Moving Average: $62.16
  • 52-Week Range: $30.00 - $70.92
  • Trailing P/E Ratio: 87.29
  • Foreward P/E Ratio: 13.43
  • P/E Growth: 1.05
  • Market Cap: $690.40M
  • Outstanding Shares: 11,580,000
  • Beta: 3
Profitability:
  • Net Margins: 7.28%
  • Return on Equity: 21.84%
  • Return on Assets: 11.84%
Debt:
  • Debt-to-Equity Ratio: 0.70%
  • Current Ratio: 3.13%
  • Quick Ratio: 2.20%
Additional Links:
Companies Related to ANI Pharmaceuticals:

Analyst Ratings

Consensus Ratings for ANI Pharmaceuticals (NASDAQ:ANIP) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $70.60 (18.42% upside)

Analysts' Ratings History for ANI Pharmaceuticals (NASDAQ:ANIP)
Show:
DateFirmActionRatingPrice TargetDetails
2/22/2017Roth CapitalDowngradeBuy -> Neutral$69.00View Rating Details
8/5/2016GuggenheimReiterated RatingBuy$65.00 -> $80.00View Rating Details
8/5/2016Oppenheimer Holdings, Inc.Boost Price TargetOutperform$65.00 -> $71.00View Rating Details
7/19/2016Citigroup Inc.UpgradeOutperform$65.00View Rating Details
6/22/2016Raymond James Financial, Inc.Initiated CoverageStrong-Buy$68.00View Rating Details
5/24/2016Standpoint ResearchDowngradeBuy -> HoldView Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/2/2017        
11/3/2016Q316$1.08$1.09$34.34 million$38.53 millionViewN/AView Earnings Details
8/4/2016Q216$0.77$1.11$27.63 million$31.30 millionViewN/AView Earnings Details
5/5/2016Q116$0.64$0.76$21.03 million$20.60 millionViewN/AView Earnings Details
2/23/2016Q415$0.60$0.52$18.13 million$18.04 millionViewN/AView Earnings Details
11/3/2015Q315$0.63$0.80$21.37 million$20.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.54$0.31$20.30 million$19.52 millionViewN/AView Earnings Details
5/5/2015Q115$0.56$0.57$19.86 million$18.80 millionViewN/AView Earnings Details
2/19/2015Q414$0.58$0.67$17.98 million$21.04 millionViewN/AView Earnings Details
11/3/2014Q314$0.46$0.66$14.60 million$17.40 millionViewN/AView Earnings Details
8/4/2014Q214$0.01($0.21)$7.95 million$6.60 millionViewN/AView Earnings Details
5/5/2014Q115$0.32$0.33$11.40 million$10.90 millionViewN/AView Earnings Details
2/27/2014Q414$0.35$5.32 million$10.53 millionViewN/AView Earnings Details
11/7/2013$0.16ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ANI Pharmaceuticals (NASDAQ:ANIP)
Current Year EPS Consensus Estimate: $4.04 EPS
Next Year EPS Consensus Estimate: $4.44 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.24$0.24$0.24
Q2 20161$0.78$0.78$0.78
Q3 20161$0.94$0.94$0.94
Q4 20161$1.06$1.06$1.06
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ANI Pharmaceuticals (NASDAQ:ANIP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ANI Pharmaceuticals (NASDAQ:ANIP)
Insider Ownership Percentage: 31.60%
Institutional Ownership Percentage: 51.56%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2016Arthur PrzybylInsiderSell37,455$66.97$2,508,361.35View SEC Filing  
8/8/2016Robert W SchrepferVPSell12,500$67.06$838,250.00View SEC Filing  
12/18/2015James G MarkenVPSell3,500$43.26$151,410.00View SEC Filing  
11/12/2015Arthur PrzybylCEOBuy2,500$40.95$102,375.00View SEC Filing  
3/19/2015James G MarkenVPSell15,000$66.50$997,500.00View SEC Filing  
9/15/2014Ross J ManganoDirectorBuy3,000$27.49$82,470.00View SEC Filing  
9/9/2014Arthur PrzybylCEOBuy1,000$26.50$26,500.00View SEC Filing  
6/18/2014James G MarkenVPSell5,000$34.28$171,400.00View SEC Filing  
5/8/2014Tracy MarshbanksDirectorSell1,381$30.02$41,457.62View SEC Filing  
5/7/2014Ross ManganoDirectorBuy2,000$30.38$60,760.00View SEC Filing  
3/21/2014Tracy MarshbanksDirectorSell21,767$31.42$683,919.14View SEC Filing  
3/20/2014Meridian Venture Partners Ii Lmajor shareholderSell20,922$32.12$672,014.64View SEC Filing  
3/19/2014Tracy MarshbanksDirectorSell25,358$33.68$854,057.44View SEC Filing  
3/18/2014Meridian Venture Partners Ii Lmajor shareholderSell60,540$34.07$2,062,597.80View SEC Filing  
3/13/2014Meridian Venture Partners Ii Lmajor shareholderSell87,723$32.48$2,849,243.04View SEC Filing  
11/7/2013Ross J ManganoDirectorBuy9,000$11.27$101,430.00View SEC Filing  
8/20/2013Ross J ManganoDirectorBuy10,000$7.47$74,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ANI Pharmaceuticals (NASDAQ:ANIP)
DateHeadline
News IconInvestor Focus: Watching Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Baldwin Journal (NASDAQ:ANIP)
baldwinjournal.com - February 23 at 1:39 AM
News IconAnalysts Take: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:ANIP)
aikenadvocate.com - February 23 at 1:39 AM
finance.yahoo.com logoANI Pharma downgraded by ROTH Capital (NASDAQ:ANIP)
finance.yahoo.com - February 22 at 8:38 PM
News IconTechnical Tracker: Watching Shares of ANI Pharmaceuticals Inc (ANIP) - Baxter Review (NASDAQ:ANIP)
baxternewsreview.com - February 22 at 3:33 PM
News IconShares on the Move Lower: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Aiken Advocate (NASDAQ:ANIP)
aikenadvocate.com - February 22 at 3:33 PM
marketexclusive.com logoAnalyst Downgrades – ANI Pharmaceuticals (NASDAQ:ANIP) Stock Gets Downgraded By Roth Capital from Buy to ... - Market Exclusive (NASDAQ:ANIP)
marketexclusive.com - February 22 at 3:33 PM
News IconStock Spotlight: Zooming in on Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - BVN (NASDAQ:ANIP)
bvnewsjournal.com - February 22 at 11:30 AM
seekingalpha.com logoFOIA Reveals Generic Alternatives For Acthar Likely To Have Very Similar Labels, Medicare Part D Exposure Remains ... - Seeking Alpha (NASDAQ:ANIP)
seekingalpha.com - February 22 at 11:30 AM
News IconANI Pharmaceuticals Inc (ANIP) is Downgraded by ROTH Capital to ” Neutral” - Highland Mirror (NASDAQ:ANIP)
www.highlandmirror.com - February 22 at 11:30 AM
News IconStock Focus: Looking at Levels for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Rives Journal (NASDAQ:ANIP)
rivesjournal.com - February 18 at 3:30 PM
News IconInvestor Radar: Focusing in on Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Benton Bulletin (NASDAQ:ANIP)
bentonbulletin.com - February 16 at 3:35 PM
finance.yahoo.com logoANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2016 Financial Results and 2017 Guidance (NASDAQ:ANIP)
finance.yahoo.com - February 16 at 3:35 PM
biz.yahoo.com logoANI PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Amendments to Articles of (NASDAQ:ANIP)
biz.yahoo.com - February 16 at 3:35 PM
News IconMarket Scope: Viewing Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Rives Journal (NASDAQ:ANIP)
rivesjournal.com - February 14 at 3:59 PM
News IconNumbers in Focus for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - The Standard (NASDAQ:ANIP)
6milestandard.com - February 13 at 3:53 PM
News IconStock Price Bolstered Mid-Session: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Aiken Advocate (NASDAQ:ANIP)
aikenadvocate.com - February 13 at 3:53 PM
News IconNarrowing in on the Numbers for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Searcy News (NASDAQ:ANIP)
searcysentinel.com - February 9 at 8:38 PM
News IconActive Trading Watch on Shares of Ani Pharmaceuticals Inc. (ANIP) - Benton Bulletin (NASDAQ:ANIP)
bentonbulletin.com - February 9 at 3:36 PM
News IconHealthcare Value Capital LLC Raised Its Ani Pharmaceuticals INC (ANIP) Holding as Market Value Rose (NASDAQ:ANIP)
randolphguide.com - February 3 at 3:42 PM
News IconStock Update: Is This Stock Fairly Valued: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Aiken Advocate (NASDAQ:ANIP)
aikenadvocate.com - February 2 at 8:38 PM
News IconCCI Level Check for Ani Pharmaceuticals Inc. (ANIP) - Market Point (NASDAQ:ANIP)
mtptnews.com - February 1 at 3:40 PM
capitalcube.com logoANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : February 1, 2017 (NASDAQ:ANIP)
www.capitalcube.com - February 1 at 3:40 PM
News IconShares Hitting the Skids Ahead of The Bell: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Aiken Advocate (NASDAQ:ANIP)
aikenadvocate.com - January 31 at 3:44 PM
investornewswire.com logoStrong Sell Recommendations Of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) At 0 - Investor Newswire (NASDAQ:ANIP)
www.investornewswire.com - January 29 at 8:33 PM
News IconTechnical Watch: ATR in View on Shares of Ani Pharmaceuticals Inc. (ANIP) - Market Point (NASDAQ:ANIP)
mtptnews.com - January 29 at 3:31 PM
News IconOff To a Slow Start in The New Year, Stock Looks For a Turnaround: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Aiken Advocate (NASDAQ:ANIP)
aikenadvocate.com - January 28 at 8:35 PM
News IconWith Markets Booming Higher, Is This Stock Fairly Valued: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Aiken Advocate (NASDAQ:ANIP)
aikenadvocate.com - January 26 at 3:50 PM
News IconWatching ADX Levels for Ani Pharmaceuticals Inc. (ANIP) - Springdale Times (NASDAQ:ANIP)
springdaletimes.com - January 25 at 8:41 PM
News IconTrading Watch: Checking in on Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - The Tribune (NASDAQ:ANIP)
lakecitytribune.com - January 25 at 3:38 PM
fool.com logo4 Top Small-Cap Stocks to Buy This Winter (NASDAQ:ANIP)
www.fool.com - January 23 at 3:37 PM
investornewswire.com logoANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:ANIP)
www.investornewswire.com - January 22 at 8:32 PM
4-traders.com logoANI Pharmaceuticals : The Wells Fargo & Company Mn Has $551,000 Position in Ani Pharmaceuticals, Inc. (Anip) (NASDAQ:ANIP)
www.4-traders.com - January 20 at 3:38 PM
prnewswire.com logoANI Announces Appointment of Karen Quinn Ph.D as Vice President Corticotropin Regulatory Affairs - PR Newswire (press release) (NASDAQ:ANIP)
www.prnewswire.com - January 19 at 4:05 PM
capitalcube.com logoANI Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ANIP) : January 19, 2017 (NASDAQ:ANIP)
www.capitalcube.com - January 19 at 4:05 PM
capitalcube.com logoANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ANIP-US : January 18, 2017 (NASDAQ:ANIP)
www.capitalcube.com - January 18 at 4:06 PM
finance.yahoo.com logoANI Announces Appointment of Karen Quinn Ph.D as Vice President Corticotropin Regulatory Affairs (NASDAQ:ANIP)
finance.yahoo.com - January 17 at 10:01 AM
News IconShorts On Watch: Ani Pharmaceuticals Incorporated (NASDAQ:ANIP ... - Baxley Report (NASDAQ:ANIP)
baxleyreport.com - January 13 at 8:42 PM
News IconCipla appoints Peter Lankau as an Independent Director on its Board (NASDAQ:ANIP)
news.webindia123.com - January 9 at 3:45 PM
News IconCipla Appoints Peter Lankau As Independent Director (NASDAQ:ANIP)
profit.ndtv.com - January 9 at 3:45 PM
News IconMarket Scope: Taking a Look at ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Wall Street Beacon (NASDAQ:ANIP)
wsbeacon.com - January 8 at 3:29 PM
fool.com logo5 Growth Stocks That Could Double (NASDAQ:ANIP)
www.fool.com - January 7 at 3:59 PM
investornewswire.com logoANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Strong Buy Recommendations At 2 - Investor Newswire (NASDAQ:ANIP)
www.investornewswire.com - January 1 at 8:32 PM
News IconChecking on Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ... - Wall Street Beacon (NASDAQ:ANIP)
wsbeacon.com - December 28 at 8:30 PM
News IconWatching the Numbers for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Wall Street Beacon (NASDAQ:ANIP)
wsbeacon.com - December 23 at 3:37 PM
streetinsider.com logoANI Pharma (ANIP) Announces Launches of Generic of Lithobid - StreetInsider.com (NASDAQ:ANIP)
www.streetinsider.com - December 22 at 3:33 PM
rttnews.com logoANI Pharma Launches Authorized Generic Of Lithobid Extended Release Tablets (NASDAQ:ANIP)
www.rttnews.com - December 21 at 4:09 PM
finance.yahoo.com logo8:30 am ANI Pharma announces launch of authorized generic of Lithobid extended release tablets (NASDAQ:ANIP)
finance.yahoo.com - December 21 at 4:09 PM
publicnow.com logoANI Pharmaceuticals Announces Launch of Authorized Generic of Lithobid® Extended Release Tablets (NASDAQ:ANIP)
www.publicnow.com - December 21 at 4:09 PM
News IconReviewing the Levels for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Business Daily Leader (NASDAQ:ANIP)
businessdailyleader.com - December 21 at 2:32 AM
streetinsider.com logoANI Pharma (ANIP) Launches Vancomycin HCl 125mg and 250mg Capsules in 50 Count Bottle (NASDAQ:ANIP)
www.streetinsider.com - December 20 at 3:46 PM

Social

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Where is ANI Pharmaceuticals' stock going? Where will ANI Pharmaceuticals' stock price be in 2017?

6 brokerages have issued 12 month price targets for ANI Pharmaceuticals' shares. Their forecasts range from $65.00 to $80.00. On average, they expect ANI Pharmaceuticals' stock price to reach $70.60 in the next year.

When will ANI Pharmaceuticals announce their earnings?

ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 2nd 2017.

Who owns ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (2.71%), Renaissance Technologies LLC (2.01%), Fiera Capital Corp (1.37%), Dimensional Fund Advisors LP (0.79%), Foresters Investment Management Company Inc. (0.76%) and GSA Capital Partners LLP (0.46%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, James G Marken and Robert W Schrepfer.

Who sold ANI Pharmaceuticals stock? Who is selling ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, State Street Corp, Cadence Capital Management LLC, Federated Investors Inc. PA, Tudor Investment Corp Et Al, GSA Capital Partners LLP, Envestnet Asset Management Inc. and Third Avenue Management LLC. Company insiders that have sold ANI Pharmaceuticals stock in the last year include Arthur Przybyl and Robert W Schrepfer.

Who bought ANI Pharmaceuticals stock? Who is buying ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Renaissance Technologies LLC, Guggenheim Capital LLC, AQR Capital Management LLC, Comerica Bank and Thrivent Financial for Lutherans.

How do I buy ANI Pharmaceuticals stock?

Shares of ANI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ANI Pharmaceuticals stock cost?

One share of ANI Pharmaceuticals stock can currently be purchased for approximately $59.62.

ANI Pharmaceuticals (NASDAQ:ANIP) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Earnings History Chart

Earnings by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Dividend History Chart

Dividend Payments by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Last Updated on 2/23/2017 by MarketBeat.com Staff